Cardiomyocytes - "Chronic cardiotoxic effects of tyrosine kinase inhibitors and anthracyclines analyzed with the FLEXcyte 96 on human iPSC-derived cardiomyocytes"
FLEXcyte 96 application note 
(0.4 MB) kindly provided by InnoVitro GmbH
Summary:
In cancer research, the intense development of targeted therapeutics such as tyrosine kinase inhibitors (TKIs) has brought tremendous improvement to the survival rate of cancer patients over the last two decades. The goal to reduce diverse toxic side effects of cancer treatment with targeted therapy has been widely achieved in comparison to traditional anti-cancer treatments like anthracyclines. Nevertheless, both therapeutics, TKIs and anthracyclines, still lead to adverse cardiotoxic side effects such as left ventricular dysfunction and heart failure.
The severity of these side effects depends on dosage and time span of treatment which brings chronic assessment of cardiotoxicity into focus.
However, acute testing (min to hours) of cell models with low predictive value remains the primary application so far, due to the inability of common cell-based assays to analyze cellular behavior reliably over prolonged periods of time.